ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

OBJECTIVE: To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). METHODS: In this phase 2 trial, 431 patients with mild to moderate AD 50 to 80 years of age were randomized 2:1 (crenezumab:placebo). Patients received low-dose subcutaneous crenezu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Jeffrey L., Cohen, Sharon, van Dyck, Christopher H., Brody, Mark, Curtis, Craig, Cho, William, Ward, Michael, Friesenhahn, Michel, Rabe, Christina, Brunstein, Flavia, Quartino, Angelica, Honigberg, Lee A., Fuji, Reina N., Clayton, David, Mortensen, Deborah, Ho, Carole, Paul, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962917/
https://www.ncbi.nlm.nih.gov/pubmed/29695589
http://dx.doi.org/10.1212/WNL.0000000000005550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962917/
https://www.ncbi.nlm.nih.gov/pubmed/29695589
http://dx.doi.org/10.1212/WNL.0000000000005550

Ejemplares similares